AstraZeneca's Triple Play: Earnings Beat, $1.5 Billion Savings Plan and a Pipeline Full of Data

AstraZeneca shares drew fresh attention on Wednesday after the drugmaker unveiled a three-year restructuring programme alongside quarterly results that cleared analyst forecasts. The stock climbed 7.1% on the session, with Reuters reporting that investors welcomed both the stronger-than-expected figures and the confirmed full-year guidance.

The savings plan is designed to free up roughly $1.5 billion a year, money the company intends to channel into its development pipeline. It also underpins AstraZeneca's ambition of hitting $80 billion in annual revenue by 2030. Getting there will not come cheap: the company expects one-off charges of up to $2 billion to implement the programme. That distinction matters — the annual relief is a projected outcome of the plan, not a result already banked, and the near-term bill lands before any of the benefits do.

Quarterly figures beat the street

For the third quarter of 2026, AstraZeneca posted revenue of $16.209 billion, a rise of 7% at constant exchange rates. Adjusted earnings per share came in at $2.79, up 19% on the same basis. Both lines landed ahead of what analysts had been looking for, giving the share price move an operational footing rather than resting solely on the promise of lower costs.

What the company did not do was raise its outlook. Management reiterated guidance for the full year 2026: constant-currency revenue growth in the mid-to-high single-digit percentage range, with adjusted EPS expanding at a low double-digit rate in constant currency. Beating the quarter while standing pat on the year is a deliberately measured message, and investors reading the rally should keep the two apart.

Enhertu clears EU regulatory hurdle

Pipeline news has been arriving in quick succession. On Tuesday, AstraZeneca and partner Daiichi Sankyo secured EU approval for Enhertu as a standalone adjuvant therapy following surgery. According to the company, the green light covers adults with operated HER2-positive breast cancer who have invasive residual disease after neoadjuvant treatment.

The approval rests on data from the DESTINY-Breast05 trial, in which Enhertu cut the risk of invasive disease recurrence or death by 53% compared with T-DM1.

Lung and gastric cancer readouts

Two Phase III readouts landed on Sunday. In the SAFFRON study, the combination of Tagrisso and Orpathys reduced the risk of disease progression or death by 45% versus platinum-based chemotherapy, while lowering the risk of death by 32%. The trial enrolled patients with EGFR-mutated non-small cell lung cancer whose disease had progressed after treatment with Tagrisso.

The CLARITY-Gastric01 trial, reported the same day, showed Sonesitatug Vedotin cutting the risk of death by 42% compared with physician's choice of treatment across the full study population. That group comprised patients with advanced Claudin-18.2-positive gastric cancer in the second or later line of therapy. Median overall survival reached 10.6 months on Sonesitatug Vedotin against 6.4 months in the comparator arm.

Analysts hold their ground

Jefferies and UBS both reaffirmed their buy ratings following the quarterly update, with price targets of 17,500 pence and 15,200 pence respectively, according to media reports. Neither move was an upgrade, and neither target was changed — the analysts are endorsing a view they already held rather than adding fresh momentum through revised valuations.

For shareholders, the story now hinges on how the operating performance and the cost programme fit together. The quarter explains the positive reception; the projected savings still have to prove themselves in practice.